Strongbone Overview

  • Status
  • Out of Business

  • Latest Deal Type
  • Liquidation

Strongbone General Information

Description

Developer of treatments intended to treat osteoporosis, rheumatoid arthritis, and peri-implantitis. The company develops treatments for diseases that are caused by bone-degrading cells called osteoclasts namely osteoporosis, rheumatoid arthritis, and peri-implantitis, enabling healthcare professionals to treat foot and bone-related ailments.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Erik Dahlbergsgatan 11A
  • 2nd Floor
  • 411 26 Gothenburg
  • Sweden

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Strongbone Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Bankruptcy: Liquidation 15-Jul-2016 Completed Startup
1. Accelerator/Incubator 27-Mar-2013 Completed Startup
To view Strongbone’s complete valuation and funding history, request access »

Strongbone Patents

Strongbone Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20140243274-A1 Novel peptide derivatives for treatment, prevention or alleviation of a condition associated with bone loss or low bone density or to inhibit osteoclast differentiation and stimulation Active 24-Jun-2009 00000000 0
US-9169289-B2 Peptide derivatives for treatment, prevention or alleviation of a condition associated with bone loss or low bone density or to inhibit osteoclast differentiation and stimulation Inactive 24-Jun-2009 00000000 0
US-20120108515-A1 Novel peptide derivatives for treatment, prevention or alleviation of a condition associated with bone loss or low bone density or to inhibit osteoclast differentiation and stimulation Active 24-Jun-2009 00000000 0
US-8748370-B2 Peptide derivatives for treatment, prevention or alleviation of a condition associated with bone loss or low bone density or to inhibit osteoclast differentiation and stimulation Inactive 24-Jun-2009 00000000 0
EP-2443136-A1 Novel peptide derivatives for treatment, prevention or alleviation of a condition associated with bone loss or low bone density or to inhibit osteoclast differentiation and stimulation Inactive 18-Jun-2009 C07K7/06 0
To view Strongbone’s complete patent history, request access »

Strongbone FAQs

  • Who is the founder of Strongbone?

    Ulf Lerner is the founder of Strongbone.

  • Where is Strongbone headquartered?

    Strongbone is headquartered in Gothenburg, Sweden.

  • What industry is Strongbone in?

    Strongbone’s primary industry is Drug Discovery.

  • Is Strongbone a private or public company?

    Strongbone is a Private company.

  • What is Strongbone’s current revenue?

    The current revenue for Strongbone is 000000.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »